Back to search results
NCT06817902

TMS Pilot in Early AD II

Enrolling by Invitation
NAAges 40–90InterventionalTreatment
HealthPartners Institute
~6 participants
Updated 2026-01-07 on ClinicalTrials.gov
What's tested:Intermittent theta burst stimulation active coilSham coil

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Effect of TBS on cognition between and within subjects using Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS)
Measured over baseline, 7 weeks

Conditions

Alzheimer Disease

Explore related trials

Alzheimer's DiseaseMild cognitive disorderAmyloid

NCT06817902

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • HealthPartners Neuroscience Center

    Saint Paul, Minnesotano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Bhavani Kashyap, MBBS, PhD · PRINCIPAL_INVESTIGATOR · HealthPartners Institute

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Established diagnosis of Mild cognitive impairment (MCI)/mild AD
Evidence for central nervous system (CNS) amyloidosis (e.g., Amyloid Positron Emission Tomography (PET) or Cerebrospinal fluid (CSF) biomarkers consistent with AD)
Prior brain imaging performed
Mini Mental Status Examination (MMSE) \>24
Clinical Dementia Rating (CDR) 0.5-1
Stable dose of cholinesterase inhibitors and memantine for at least one month
Subjects are between 40-90 years of age

Exclusion

Non-AD dementia including, but not limited to, Lewy body dementia, frontotemporal dementia, vascular dementia, Jakob-Creutzfeldt disease, etc.
Inability to tolerate resting state-function magnetic resonance imaging (rs-fMRI)
Contraindication of rs-fMRI due to implants or metal
Seizure disorder

What this trial measures

  • Effect of TBS on cognition between and within subjects using Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS)baseline, 7 weeks

    Average change of RBANS total score in TMS arm compared to the average change in RBANS total score in the sham arm. Range \[-160 to 160\]. Positive comparison of TMS arm to sham arm indicates increased cognitive scores in TMS arm.